Utilizing left atrial strain to identify patients at risk for atrial fibrillation on ibrutinib

Singh, Arushi; Hangouche, Nadia El; McGee, Katherine; Gong, Fei; Lentz, Robert W.; Feinglass, Joseph; Akhter, Nausheen

doi:10.1111/echo.14946

Cited by 11 publications

(6 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As far as we know, this is the first time that baseline LA area and diameter prove to predict the occurrence of AF in patients treated with ibrutinib with a well‐defined cut off value. Other echocardiographic parameters, such as LA strain, 21 have emerged as predictors of IRAF, although its incorporation into clinical practice might not be as feasible as its interpretation requires specialistic expertise.…”

Section: Discussionmentioning

confidence: 99%

“…Various studies have analyzed the risk factors predicting the development of IRAF: interestingly, although a higher incidence in patients with known cardiovascular comorbidities (i.e., hypertension, mitral valve disease, coronary artery disease (CAD)) has been suggested, ibrutinib has shown to increase the risk of IRAF independently from these conditions 19–23 …”

Section: Introductionmentioning

confidence: 99%

“…18 Various studies have analyzed the risk factors predicting the development of IRAF: interestingly, although a higher incidence in patients with known cardiovascular comorbidities (i.e., hypertension, mitral valve disease, coronary artery disease (CAD)) has been suggested, ibrutinib has shown to increase the risk of IRAF independently from these conditions. [19][20][21][22][23] Further investigation is needed to define predictors of IRAF and guide clinical practice, considering that the proper management of concomitant Ibrutinib and anticoagulant therapy requires a close cooperation between the hematologist and an expert cardiooncologist and has yet to be defined. 6,24 The present study, following preliminary data published in 2017, 22 is a single-center 5-year follow-up analysis of predictors of IRAF in 43 patients affected by CLL treated with ibrutinib, focusing on comorbidities, electrocardiographic features (12-derivation electrocardiography (ECG), 24h monitoring in selected cases) and transthoracic echocardiography (TTE).…”

mentioning

confidence: 99%

See 2 more Smart Citations

Predictors of ibrutinib‐associated atrial fibrillation: 5‐year follow‐up of a prospective study

Mattiello

Barone

Giannarelli

et al. 2023

Hematological Oncology

View full text Add to dashboard Cite

Ibrutinib‐associated atrial fibrillation (IRAF) emerged among the adverse events of major interests in ibrutinib‐treated patients as real‐world studies showed a higher incidence compared to clinical trials. We prospectively analyzed predictors of IRAF in 43 single‐center consecutive patients affected by chronic lymphocytic leukemia that started therapy with ibrutinib between 2015 and 2017. Key secondary endpoints were to describe the management of IRAF and survival outcomes. During a median follow‐up period of 52 months, we registered 45 CV events, with a total of 23 AF events in 13 patients (CI 30.0% (95% CI: 16.5–43.9)). Pre‐existent cardiovascular risk factors, in particular hypertension, a previous history of AF and a high Shanafelt risk score emerged as predictors of IRAF. Baseline echocardiographic evaluation of left atrial (LA) dimensions confirmed to predict IRAF occurrence and cut‐off values were identified in our cohort: 32 mm for LA diameter and 18 cm2 for LA area. No difference in progression free survival and overall survival emerged in patients experiencing IRAF. Following AF, anticoagulation was started in all eligible patients, and cardioactive therapy was accordingly modified. Echocardiography represents a highly reproducible and widespread tool to be included in the work‐up of ibrutinib candidates; the identification of IRAF predictors represents a useful guide to clinical practice.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Predictors of ibrutinib‐associated atrial fibrillation: 5‐year follow‐up of a prospective study

Mattiello

Barone

Giannarelli

et al. 2023

Hematological Oncology

View full text Add to dashboard Cite

show abstract

“…Among those with more than 1 CVD risk factor (eg, age >50 years, prior cardiac arrhythmia, hypertension, heart failure, moderate or greater valvular disease, prior cardiotoxic therapy administration), a baseline echocardiogram is also recommended. 14 , 28 …”

Section: Btk Inhibitor-associated Afmentioning

confidence: 99%

Cardiovascular Toxicities of BTK Inhibitors in Chronic Lymphocytic Leukemia

Quartermaine,

Ghazi,

Yasin

et al. 2023

JACC: CardioOncology

View full text Add to dashboard Cite

“…DOI: https://doi.org/10.17816/DD108243 ассоциируется с высоким процентом случаев фибрилляции предсердий, недавнее исследование A. Singh и соавт. [56] показало хорошую прогностическую ценность стрейна ЛП у данной группы пациентов.…”

Section: A R T I C L E I N P R E S Sunclassified

Left atrial longitudinal strain analysis in diagnostic of cardiotoxicity

Yusupova

Yusupov²

2022

Digital Diagnostics

View full text Add to dashboard Cite

A wide range of extremely effective chemotherapy drugs has a negative effect on the cardiovascular system, leveling the success of oncological treatment. Early diagnosis of cardiotoxicity is extremely important, allowing timely application of preventive and therapeutic measures. Evaluation of the left ventricular ejection fraction using echocardiography is the basic non-invasive instrumental method for assessing cardiac function and the main guideline in diagnosing cardiac dysfunction during chemotherapy. However, if dysfunction is subclinical the ejection fraction can remain normal for a long time, and also has a pronounced inter-operator variability and dependence on volumetric load. Specialists are constantly in search of optimal echocardiographic parameters that allow diagnosing cardiac dysfunction in the early stages. Analysis of the global longitudinal deformation of the left atrium seems to be a promising method for these purposes. A large amount of accumulated data suggests that the left atrium is not just a conduit chamber, but reflects the filling pressure of the left ventricle, being a sensitive marker of its systolic and diastolic dysfunction. This review presents an analysis of currently available studies on the application of the methodology for assessing the global longitudinal deformation of the left atrium in the diagnosis of cardiac dysfunction in use of cardiotoxic drugs.

show abstract

Utilizing left atrial strain to identify patients at risk for atrial fibrillation on ibrutinib

Cited by 11 publications

References 25 publications

Predictors of ibrutinib‐associated atrial fibrillation: 5‐year follow‐up of a prospective study

Predictors of ibrutinib‐associated atrial fibrillation: 5‐year follow‐up of a prospective study

Cardiovascular Toxicities of BTK Inhibitors in Chronic Lymphocytic Leukemia

Left atrial longitudinal strain analysis in diagnostic of cardiotoxicity

Contact Info

Product

Resources

About